Patients undergoing CAR T-cell therapy often encounter cytokine release syndrome (CRS), a severe adverse event triggered by systemic levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumour necrosis factor (TNF), and interferon-gamma (IFN-γ) (Ref 83). The gene discussed is IFNG; the disease is congenital rubella syndrome.